[Photo by Deltaworks on Pixabay]
February 21, 2026 (Saturday) – Yeojun Jung
A large international genomic study published Feb. 19, 2026, in Science has mapped the cancer genome of domestic cats and identified multiple tumor-driving mutations that also appear in human cancers, including aggressive breast cancer.
The research analyzed DNA from 493 naturally occurring feline tumors matched with normal tissue samples and covering 13 cancer types collected through veterinary diagnostic networks.
Scientists sequenced feline equivalents of about 1,000 genes already known to drive cancer in humans in order to directly compare mutation patterns between species.
The study found that the tumor-suppressor gene TP53 was the most frequently mutated gene across the feline cancers.
Researchers also identified recurring genomic alterations, including deletion of PTEN or FAS and amplification of MYC, three gene disruptions widely associated with tumor survival and uncontrolled growth in human oncology.
Across the dataset, the team identified 31 confirmed cancer driver genes together with mutational signatures, viral DNA fragments, and inherited genetic variants linked to cancer susceptibility.
The authors concluded that the domestic cat oncogenome shows strong structural overlap with known human cancer mutation pathways.
A university research summary of the project reported that these genomic parallels extend across cancers affecting the blood, lungs, bone, skin, gastrointestinal tract, and nervous system.
Among the strongest disease-specific overlaps were malignant feline mammary tumors, which show both molecular similarities and aggressive clinical behavior comparable to certain human breast cancers.
Feline mammary carcinoma is one of the most lethal cancers affecting domestic cats and often progresses rapidly after diagnosis.
The summary identified seven major driver genes linked to feline mammary tumor formation and reported that FBXW7 mutations appeared in more than half of the mammary cancer samples analyzed.
Human breast cancer studies have previously associated FBXW7 mutations with poorer survival outcomes, providing a direct genetic comparison point between the species.
Laboratory tissue experiments cited in the summary found that feline tumor cells with FBXW7 mutations showed higher sensitivity to specific chemotherapy drugs under controlled experimental conditions.
Those findings were limited to laboratory testing and were not reported as confirmed clinical treatment outcomes.
Because the tumors analyzed developed spontaneously in household pets rather than being artificially induced in laboratory animals, the cancers reflect real environmental exposure, aging, and genetic diversity.
Researchers described this natural disease progression as a key factor allowing cross-species comparison of how tumors form, mutate, and spread over time.
The study was built through collaboration between genomic sequencing centers, veterinary pathologists, and clinical institutions supplying diagnostic tumor samples.
This structure enabled the project to assemble one of the largest feline cancer genomic datasets yet published.
The research frames its findings within a comparative oncology model linking veterinary and human cancer biology and identifying conserved mutation pathways shared across species.
The authors state that mapping the domestic cat oncogenome allows alignment of feline mutations with known human cancer gene networks and enables identification of potentially actionable mutation targets for future research.
As part of the project, the research team released a public genomic database derived from the sequenced tumors to support further investigation into tumor classification, mutation-driven therapy research, and comparative oncology studies.
The dataset is intended to allow researchers to examine tumor evolution patterns and treatment-response hypotheses using the same cross-species genomic reference.
The published oncogenome is presented as a foundational reference resource for future cancer genomics research involving domestic cats and cross-species mutation analysis, including ongoing investigations into aggressive breast cancer biology.
